TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Endothelial function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12 hour fasting lipid profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PCSK9 levels change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Allergic reaction to egg
Endpoint domain: Adverse events/effects
Primary endpoint: Tibial union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient-rated leg pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lipid lowering effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamic Gait Index test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walk Test of 10 meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Unanticipated Serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Technical Feasibility as Assessed by the Ability of the InFlux Device to Deliver RF Energy to Target Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alteration of soluble ST2 concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a 2-point Improvement in Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients with effective OPAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-emergent Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Venous Thromboembolism (VTE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of samples collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Remission of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Participants with 12-lead ECG Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Participants with Clinical Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dimensional change of free gingival graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in total free gingival graft area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' quality of life as measured by FACT-Leukemia Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in serum hepatitis B virus (HBV) DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Daily Average Number of Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Loss of Psoriasis Area and Severity Index (PASI) 75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Level of MGluR5 PET binding in dorsolateral prefrontal cortex (DLPFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum tolerated dose of terameprocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in terameprocol tumor to plasma concentration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated days of terameprocol dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events and/or Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived patient pain assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptable Technical Success of the LAMPOON Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Optimal Technical Success of the LAMPOON Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in total gastrointestinal symptom rating scale (GSRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Toxicity rate (grade 3 and 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Improved Coronary Flow Reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMI major hemorrhage within 48 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Elevation of specific pertussis antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative new-onset atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Carotid Total Plaque Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Number of Fitting Modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients initiating vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall incidence of treatment-emergent AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of autoimmune effects
Endpoint domain: Adverse events/effects
Primary endpoint: Higher percentages of FOXP3+ T regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal Respiratory Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal Voluntary Grip Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: emotional status of caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional mobility performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to cervical cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Blood lipid responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of neurological events or vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bile duct clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnosis of Acute Mountain Sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medication consumption rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ocular and non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum depth of protoporphyrin IX (PpIX) fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pharmacokinetic profile of HCV-796
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PRO symptom measurement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Leukocyte radical oxygen species (ROS) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ulcer reduction percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation Dermatitis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in total asthma symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Assessment of Cenicriviroc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Assessment of Dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Assessment of Midazolam and alpha-hydroxymidazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural success during the first 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from device related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-prandial insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathologic complete response rate (pCR)
Endpoint domain: Mortality/survival
Primary endpoint: 3-year disease free survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Mean Numeric Pain Rating Scale (NPRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target effect-site concentration of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients free-from AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of active smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiometabolic biomarker risk factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of HS recordings correlating with clinical findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Life of Children and Youth
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline on the Social Responsiveness Scale (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline on the Brief Observation of Social Communication Change (BOSCC)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Fine motor domain of Peabody Developmental Motor Scales-2nd edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal bacterial microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Glucose Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HDL (High-Density Lipoprotein)-Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hematocrit Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: steady-state pharmacokinetics of TMC125
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state concentrations of LPV/low dose ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month incidence of recurrent VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: C/D Ratio measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomechanical gait initiation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leibowitz Social Anxiety Scale - Self Report (LSAS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in corticomotor excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative incidence of major and minor bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of access site vascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in satiety scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acylated ghrelin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immunogenicity based on CMV specific cell-mediated immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean density of contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Effective Survival
Endpoint domain: Mortality/survival
Primary endpoint: Procedural success of chronic total occlusion PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of polybacterial urine analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients achieving excellent coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosis of cardiac sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of preoperative biometry in predicting postoperative equivalent refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain measured on Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidural analgesia effectiveness during birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cycloguanil formation clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Competitive Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Amounts of leucocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SOWS-Gossop score on Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-to-dropout
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: RBC transfusion independence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: spleenic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in FEV1 from baseline to week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Psoriasis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour Objective Cough Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MRI imaging changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in functional class status (NYHA Class)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in 6-minute hall walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Assessed by Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 12-lead Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Clinical Laboratory Tests (CLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of the maximum measured concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence and severity of patient-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in workflow pattern
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Device Preference Based on Dose Counter Size
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of complicated twin pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: percent change from baseline in [123I]ß-CIT/SPECT striatal uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: remission intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LASIK flap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular occlusive events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mobilisation of CD34+ hematopoietic stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dyspnea as Measured by Oxygen Cost Diagram (OCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CKD progression measured by changes in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cardiovascular risk measured by CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ovulatory cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with any biological intolerability or adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in BPRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Short Physical Performance Battery at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline One leg standing test at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Timed Up and Go test at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Appropriate Antimicrobial Prescriptions Recommended
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Effectiveness Assessed by User Acceptance of the Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in burden of overall GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma glycolate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of the Affected Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of RO4929097
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of Hamstring Muscle Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of Hamstring Structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to Prior Level of Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of resolution of shivering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of blood MAIT cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression Free Rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in the modified Piper Fatigue Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in the Minnesota Living with Heart Failure Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major vascular event
Endpoint domain: Mortality/survival
Primary endpoint: specific immunological changes (IgG, IgG1, IgG4, IgE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1-year non relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of M II oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in brachial artery smooth muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of EBI-005 (vital signs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of EBI-005 (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of EBI-005 (assessment of antibody development)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of EBI-005 (laboratory changes over time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes